Last updated on April 18, 2014 at 7:49 EDT

Latest Creabilis Stories

2013-09-18 04:22:57

CANTERBURY, England, September 18, 2013 /PRNewswire/ -- Creabilis, a late clinical stage European dermatology company with a focus on pruritus (itch), today announces it has treated the first patients in its Phase 2b study of its lead product, CT327, in patients with atopic dermatitis (AD). The Phase 2b trial is a multi-centre, randomised, double-blind, placebo-controlled study in adult and adolescent patients (older than 12 years) with mild to moderate atopic...